Before founding DreamSystems, Timothy C. Melkus served as Senior Vice President, Development Operations at LifeCycle Pharma (LCP), a public bio-pharmaceutical company that underwent an ill-advised name change to Veloxis Pharmaceuticals. While there, Melkus led global development of ENVARSUS XR (tacrolimus extended-release tablets). Before joining LCP, Melkus served as senior vice president, business development and operations at IDM Pharma Inc., a public biopharma company that received approval for the immune response modifier MEPACT in Europe. IDM was acquired by Takeda America Holdings Inc., or Takeda, in June 2009. Before IDM, Melkus served as vice president, business development at NeoPharm Inc., a public biopharma company. From 1999 to 2008, Melkus formed a boutique healthcare consulting practice focused on strategic and tactical planning, business development, manufacturing strategy, trade relations and channel management projects included MedPointe, Merisant, NeoPharm, Pharmacia, Serono and US Pharmacopeia. From 1984 to 1998, he held a variety of information technology, operations, business development, and profit analysis roles with increasing responsibility at G.D. Searle and Monsanto Growth Enterprises.
Melkus received his Master of Business Administration in Finance from the Kellogg School of Management at Northwestern University, and his Bachelor of Science in General Education from Northwestern University in Evanston, Illinois. He is a Sustaining Fellow and Emeritus member of the Auxiliary Board for the Art Institute of Chicago.
